A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL346 in Healthy Caucasian and Japanese Adult Subjects
Latest Information Update: 17 Sep 2019
At a glance
- Drugs CSL 346 (Primary) ; CSL 346 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors CSL
- 17 Sep 2019 Status changed from recruiting to completed.
- 13 Dec 2018 Planned number of patients changed from 80 to 116.
- 13 Dec 2018 Planned End Date changed from 13 Dec 2018 to 30 Jun 2019.